Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: Effect of drug efflux transporters and lipid solubility

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 1118-1125

  Cygalova, Lenka Hahnova ^a   Hofman, Jakub ^a   Ceckova, Martina ^a   Staud, Frantisek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BODIPY; BREAST CANCER RESISTANCE PROTEIN; GLIBENCLAMIDE; GLYCOPROTEIN P; PRAZOSIN; RHODAMINE 123; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, RAT; BODIPY FL PRAZOSIN; BODIPY-FL PRAZOSIN; BORON DERIVATIVE; DRUG DERIVATIVE; LIPID;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PLACENTA BARRIER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG TRANSPORT; EFFUSION; FEMALE; LIPID SOLUBILITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MOTHER FETUS RELATIONSHIP; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; DOSE RESPONSE; ENZYME SPECIFICITY; FETOMATERNAL TRANSFUSION; IN VITRO STUDY; METABOLISM; PERFUSION; PLACENTA; PREGNANCY; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BORON COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYBURIDE; LIPIDS; MATERNAL-FETAL EXCHANGE; P-GLYCOPROTEIN; PERFUSION; PLACENTA; PRAZOSIN; PREGNANCY; RATS; RHODAMINE 123; SOLUBILITY; SUBSTRATE SPECIFICITY;

EID: 73349125786     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160564     Document Type: Article

References (41)

1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, et al. (2004) Prescription drug use in pregnancy. Am J Obstet Gynecol 191:398-407.
2. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, Smith DH, et al. (2006) Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 15:546-554.
3. Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, and Tümmler B (1992) Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem 206:137-149.
4. Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, and Staud F (2006) Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33:58-65.
5. Ceckova-Novotna M, Pavek P, and Staud F (2006) P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 22:400-410.
6. Cygalova L, Ceckova M, Pavek P, and Staud F (2008) Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat. Toxicol Lett 178:176-180.
7. de Bruin M, Miyake K, Litman T, Robey R, and Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126.
8. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665-15670.
9. Elliott BD, Langer O, Schenker S, and Johnson RF (1991) Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 165:807-812.
10. Elliott BD, Schenker S, Langer O, Johnson R, and Prihoda T (1994) Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 171:653-660.
11. Evseenko DA, Paxton JW, and Keelan JA (2006) ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol 290:R1357-R1365.
12. Gedeon C, Anger G, Piquette-Miller M, and Koren G (2008) Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta 29:39-43.
13. Gedeon C, Behravan J, Koren G, and Piquette-Miller M (2006) Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 27:1096-1102.
14. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, and Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90:526-536.
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
16. Kavallaris M (1997) The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 8:17-25.
17. Kimchi-Sarfaty C, Gribar JJ, and GottesmanMM(2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 62:1-6.
18. Koren G (2001) Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol 15:227-229.
19. Kraemer J, Klein J, Lubetsky A, and Koren G (2006) Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 195:270-274.
20. Langer O, Conway DL, Berkus MD, Xenakis EM, and Gonzales O (2000) A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 343:1134-1138.
21. Leazer TM and Klaassen CD (2003) The presence of xenobiotic transporters in rat placenta. Drug Metab Dispos 31:153-167.
22. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
23. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
24. Mao Q (2008) BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res 25:1244-1255.
25. Mao Q and Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133.
26. Masereeuw R, Moons MM, and Russel FG (1997) Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur J Pharmacol 321:315-323.
27. Nanovskaya TN, Nekhayeva I, Hankins GD, and Ahmed MS (2006) Effect of human serum albumin on transplacental transfer of glyburide. Biochem Pharmacol 72:632-639.
28. Novotna M, Libra A, Kopecky M, Pavek P, Fendrich Z, Semecky V, and Staud F (2004) P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod Toxicol 18:785-792.
29. Pávek P, Fendrich Z, Staud F, Malákova J, Brozmanová H, Láznícek M, Semecký V, Grundmann M, and Palicka V (2001) Influence of P-glycoprotein on the transplacental passage of cyclosporine. J Pharm Sci 90:1583-1592.
30. Pavek P, Staud F, Fendrich Z, Sklenarova H, Libra A, Novotna M, Kopecky M, Nobilis M, and Semecky V (2003) Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J Pharmacol Exp Ther 305:1239-1250.
31. Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859-1876.
32. Pollex E, Lubetsky A, and Koren G (2008) The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29:743-747.
33. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
34. Sivan E, Feldman B, Dolitzki M, Nevo N, Dekel N, and Karasik A (1995) Glyburide crosses the placenta in vivo in pregnant rats. Diabetologia 38:753-756.
35. Staud F and Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720-725.
36. Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, Cygalova L, Nachtigal P, and Fendrich Z (2006) Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 319:53-62.
37. Utoguchi N, Chandorkar GA, Avery M, and Audus KL (2000) Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells. Reprod Toxicol 14:217-224.
38. van der Kolk DM, de Vries EG, Müller M, and Vellenga E (2002) The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 43:685-701.
39. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, and Breimer DD (2000) Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 11:207-214.
40. Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, and Mao Q (2006) Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab 291:E1295-E1304.
41. Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, and Mao Q (2008) The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73:949-959.